An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor’s Eczema Treatment on Two QVC® Shows on February 7
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals (NYSE American: NBY) announces that Chief Product Officer Dr. Audrey Kunin will be featured on two QVC shows on February 7, 2023. She will promote the Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm at 2 p.m. ET and 9 p.m. ET. This balm is designed to relieve eczema flare-ups common in winter and has obtained the National Eczema Association Seal of Acceptance. Its formulation includes 1% colloidal oatmeal and dermatological botanicals that enhance skin hydration and relief. The initiative aligns with targeting an estimated 31 million Americans suffering from eczema, highlighting its market potential.
Positive
Feature on popular QVC shows increases product visibility.
Product has earned the National Eczema Association Seal of Acceptance.
Targets a significant market of 31 million Americans with eczema.
Negative
None.
Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on “It Takes Two with Mary & Sandra” at 2 p.m. ET and “Girl’s Night In With Courtney & Jane” at 9 p.m. ET
EMERYVILLE, Calif.--(BUSINESS WIRE)--
NovaBay®Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor®’s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “It Takes Two With Mary & Sandra” at 2 p.m. Eastern time and on “Girl’s Night In With Courtney & Jane” at 9 p.m. Eastern time.
“This is the ideal time of year for our moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm as eczema flare-ups occur more frequently in the winter months due to cold weather and dry air from indoor heating systems,” said Dr. Kunin. “Our clinical-strength, high-potency balm helps to temporarily relieve eczema, rashes, redness, dryness and itchiness and is suitable for the whole family wherever eczema strikes. Our product packaging proudly features the National Eczema Association Seal of Acceptance™ for meeting the Association’s rigorous standard for providing benefits and improving the quality of life for people with eczema and sensitive skin.
“It’s exciting to appear on these two popular QVC shows to spotlight the significant benefits of Calm Cool + Corrected Eczema Clinical Repair Balm,” added Dr. Kunin. “QVC attracts a demographic that complements our social media promotions to reach the estimated 31 million Americans with eczema who may benefit from our product.”
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm features eczema-active 1% colloidal oatmeal with enhanced beta glucan to help relieve minor skin irritations and itching, together with an advanced complex of ceramides and essential lipids to maximize hydration and dermatologic botanicals that calm and soothe the skin.
Dr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry. She founded DERMAdoctor to formulate and commercialize highly effective, prestige solutions for common skincare concerns that have been overlooked by the beauty industry. DERMAdoctor delivers on the promise that clinical skin therapy can be simple and easy to use, while providing significant and measurable results. DERMAdoctor products are developed to provide real solutions for real people with real skin-related concerns.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
What shows will NovaBay Pharmaceuticals feature its eczema balm on?
NovaBay Pharmaceuticals will feature its eczema balm on 'It Takes Two with Mary & Sandra' at 2 p.m. ET and 'Girl's Night In with Courtney & Jane' at 9 p.m. ET on February 7, 2023.
What is the primary benefit of the Calm Cool + Corrected eczema balm?
The Calm Cool + Corrected eczema balm is formulated to relieve eczema, rashes, redness, dryness, and itchiness, particularly during winter flare-ups.
How does the National Eczema Association certify the eczema balm?
The eczema balm has received the National Eczema Association Seal of Acceptance for meeting rigorous standards for providing benefits to individuals with eczema.
What potential market does NovaBay Pharmaceuticals aim to reach with their product?
NovaBay Pharmaceuticals aims to reach an estimated 31 million Americans who suffer from eczema.
